A quarterly Philippine longevity-market watch: claims, regulation, and new evidence

TL;DR

• Philippine food-supplement rules bar clinical therapeutic claims and require a clear “NO APPROVED THERAPEUTIC CLAIMS” label, so product category matters before any science is discussed.¹
• A new 12-week pilot in older adults doubled blood NAD+ but did not improve cognition, total brain blood flow, or blood pressure.²
• Across eight short randomized NMN trials, pooled results found no significant gains in the measured glucose-control or lipid-profile outcomes.³
• New MOTS-c research found mitochondrial changes in transgenic mice, while its human exercise experiment did not show a matching blood difference across the exercising leg.⁴

For Filipino readers, a quarterly longevity watch is less about chasing every fresh headline and more about sorting three separate questions. What does the claim actually promise? What does Philippine regulation say about the product category? What did the research measure, and in which model? Keeping those questions apart makes the next advertisement, podcast clip, or study abstract easier to read without turning caution into cynicism.

Start with a practical meaning of longevity

Longevity can become a vague container for energy, appearance, memory, metabolism, or a longer life. A more useful public-health anchor is healthy ageing. WHO defines it as maintaining the functional ability that supports wellbeing in older age.⁵ That includes mobility, decisions, relationships, basic needs, and contributing to society.⁵

This wider frame changes the reading task. A blood marker is not the same as function. A cell pathway is not the same as wellbeing.⁶ A short experiment can answer a narrow question without settling the larger one. A simple reader check uses three boxes: endpoint, setting, and time. Then compare that result with the actual claim being made.

NAD+ is named here only as the neutral catalog reference below.

The Philippine rulebook begins with category

For a Philippine market watch, the label “supplement” carries specific limits. The Philippine FDA says food or dietary supplements shall not have clinical therapeutic indications or therapeutic claims.⁷ Its current manual also excludes parenteral and sublingual forms from the food-supplement category.¹ Form, intended purpose, and product category therefore belong in the same regulatory check.¹

The label supplies another clue. Registered food or dietary supplements must display “FOOD SUPPLEMENT” and “NO APPROVED THERAPEUTIC CLAIMS” on the main panel.¹ That sentence is not decorative fine print. It marks a boundary between a supplement listing and a therapeutic claim.⁷

This gives Filipino readers a clean first pass. Start by copying the exact category shown on the item. A science term on a label does not erase the rules attached to the product category.

Check the exact record, not a familiar ingredient

Philippine FDA guidance says health products need proper authorization.⁸ The agency directs readers to check food-product records in its Verification Portal by brand, product name, or registration number.⁸ That is more precise than searching only for a familiar ingredient.

An exact record matters because similar front-label words can sit on different brands, forms, or registrations. The portal check should match the item in front of the reader, not a neighboring result that merely sounds related.⁸ A registration record also answers a regulatory question about that exact entry; it does not reproduce a clinical trial or settle a broad longevity claim.⁸

A useful quarterly habit is to save the exact product name, claimed category, registration number, and wording of the promise. Those four details make later comparisons clearer and prevent a general science discussion from standing in for a product-specific check.

NAD+ headlines often begin with a biomarker

NAD+ is involved in cellular energy metabolism, redox balance, and signaling.⁶ Nicotinamide riboside and nicotinamide mononucleotide are precursor compounds studied as ways to raise circulating NAD+.⁶ The 2026 review found that this biochemical change can occur while reported clinical benefits remain dependent on context.⁶

That distinction is the center of the NAD+ story. “Raised NAD+” describes target engagement: a biological measure moved in the expected direction.⁶ It does not automatically mean that memory, mobility, symptoms, or healthspan also changed.⁶ Those outcomes need their own measurements and comparisons.

For a reader, the fastest test is to circle the main endpoint. A memory headline outruns a study that mainly reports a blood marker.⁶ The mechanism may still matter, but it cannot fill in an unmeasured human result.

A new cognitive pilot keeps those endpoints apart

A July 2026 phase II pilot offers a timely example. Forty-two older adults with amnestic mild cognitive impairment completed a 12-week randomized, placebo-controlled study.² Nicotinamide riboside doubled blood NAD+ in the intervention group.² Yet the trial did not report improvement in its cognition outcome, total cerebral blood flow, or blood pressure.²

The paper also reported exploratory regional blood-flow signals.² Those analyses were not corrected for multiple comparisons, so the authors framed them as findings for later study rather than confirmation of the main result.² The trial was also short and small.²

The informative reading is not “nothing happened.” A biomarker changed, while several brain and body outcomes did not improve during this study.² Both parts belong in any fair account of the result.²

Metabolic findings need their population labels

The NMN record shows why one result should not erase another. A 10-week randomized trial in postmenopausal women with prediabetes and overweight or obesity reported higher muscle insulin sensitivity and insulin signaling after NMN.⁹ That is a positive human finding in a defined population and for defined endpoints.⁹

A later meta-analysis combined eight randomized trials involving 342 mainly non-diabetic middle-aged or older adults.³ It found no significant NMN benefit for the measured glucose-control or lipid-profile outcomes.³ The included studies lasted from 14 days to 12 weeks.³

These records ask different questions because their populations, outcomes, and analysis levels differ.¹⁰ The fair summary keeps the specific positive muscle result and the pooled null metabolic findings visible together.¹⁰ Neither should be stretched into a verdict about lifespan, every adult, or every outcome.

MOTS-c is named here only as the neutral catalog reference below.

MOTS-c remains a model-sensitive story

MOTS-c is a regulatory peptide encoded by a short open reading frame in mitochondrial DNA.¹¹ That identity explains the interest in mitochondrial signaling, but it does not establish a human longevity outcome.¹¹

In a 30-person study, researchers compared endurance exercise, resistance exercise, and a control condition.¹² Circulating MOTS-c showed a trend after endurance exercise, while measured mitochondrial-peptide levels did not correlate with fitness outcomes.¹² A trend in blood is not a performance result.¹²

A 2026 paper added a different layer. It reported changes in muscle mitochondrial performance in two transgenic mouse strains exposed to MOTS-c.⁴ In the same paper, a human one-leg exercise experiment found no arterio-venous MOTS-c difference.⁴ The mouse finding does not establish the same functional outcome in people.⁴ The mouse work and human exercise sampling answer different questions.⁴

Bottom line

A useful Philippine longevity watch runs on three columns: claim, regulatory category, and measured evidence. Philippine FDA rules keep supplement claims and labels within a defined boundary.⁷ The agency’s Verification Portal helps readers match that check to an exact food-product record.⁸ Research then needs a second filter. The new cognitive pilot changed blood NAD+ without improving its main cognition result.² NMN findings differ across a specific trial and a broader pooled analysis because the questions differ.¹⁰ MOTS-c findings also stay attached to their human or mouse model.⁴ Each quarter, the disciplined move is to preserve those labels before drawing a conclusion.

This article is educational research context, not medical advice. Catalog links are neutral references and do not imply a treatment or human-use recommendation.

Frequently asked questions

What should I record when I see a longevity claim?

Write down the exact promise, product category, measured endpoint, study population or model, and study period. For a Philippine food-product check, also copy the brand, product name, and registration number. The FDA Verification Portal is designed for searches using those exact details.⁸

Does a Philippine supplement registration confirm a longevity result?

A food-product record answers a regulatory question about the exact registered entry.⁸ Philippine FDA rules separately say supplements shall not carry clinical therapeutic claims.⁷ Treat the record and the research paper as two different documents with two different jobs, even when they share an ingredient name.

Why is “NO APPROVED THERAPEUTIC CLAIMS” important?

The phrase is a required main-panel declaration for food or dietary supplements under the Philippine FDA manual.¹ It marks the category being presented.¹ It does not summarize every study on an ingredient, but it sets a clear limit on therapeutic promotion.⁷

Does higher blood NAD+ mean better memory?

Not by itself. In the new 12-week pilot, nicotinamide riboside doubled blood NAD+, yet cognition did not improve.² Total brain blood flow and blood pressure also did not improve.² The blood result and the cognition result are separate endpoints and should remain separate.

How can one NMN trial be positive when a meta-analysis is null?

The positive trial focused on muscle insulin sensitivity in postmenopausal women with prediabetes and overweight or obesity.⁹ The meta-analysis pooled eight short trials in mainly non-diabetic middle-aged or older adults and examined several glucose and lipid markers.³ Different populations and endpoints can produce different answers.¹⁰

What does the latest MOTS-c study add?

The 2026 paper reported mitochondrial changes in two transgenic mouse strains.⁴ Its human one-leg exercise experiment found no matching MOTS-c difference across the exercising leg.⁴ The paper therefore adds mechanistic animal detail and a narrow human sampling result, not one combined human longevity outcome.⁴

Sources

Footnotes

1. Manual on the Registration Application of Food or Dietary Supplements. Philippine FDA classification and labeling requirements for registered food or dietary supplements. The rule describes classification and labeling; it does not establish a clinical outcome. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

2. A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment. Double-blind, placebo-controlled phase II pilot trial in older adults with amnestic mild cognitive impairment. The trial was short and small; exploratory regional blood-flow findings were not corrected for multiple comparisons. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹²

3. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Trials lasted 14 days to 12 weeks and reported at least one glucose-control or lipid outcome. The pooled result applies to the included short trials and their measured metabolic markers. ↩ ↩² ↩³ ↩⁴ ↩⁵

4. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. The paper combined administered MOTS-c experiments in transgenic mice with a human exercise sampling experiment. The mouse intervention result does not establish a matching human functional outcome, and the human component did not test such an outcome. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

5. Healthy ageing and functional ability. WHO public-health definition of healthy ageing and functional ability. This framework is broader than a biomarker or a single laboratory measurement. ↩ ↩²

6. NAD+ biology and supplementation: From mechanisms to clinical perspectives. A 2026 review connecting NAD+ biology with clinical research on precursor compounds. Biochemical target engagement does not by itself establish better function, symptoms, or healthspan. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

7. Manual on the Registration Application of Food or Dietary Supplements. Current Philippine FDA registration and classification guidance for food or dietary supplements. This is a product-category and claims rule, not a finding about the effect of any ingredient. ↩ ↩² ↩³ ↩⁴ ↩⁵

8. FDA Advisory No. 2026-0756. A 2026 Philippine FDA advisory explaining authorization and official record checks. A search must concern the exact product record; a similar ingredient name is not the same record. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

9. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Double-blind, placebo-controlled human trial in a specific metabolic and demographic group. This population-specific result should not be generalized to all adults or to broader longevity outcomes. ↩ ↩² ↩³

10. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials; Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Comparison of one population-specific randomized trial with a meta-analysis of eight short randomized trials. The records should be read together without erasing either the specific positive finding or the pooled null findings. ↩ ↩² ↩³ ↩⁴

11. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Mechanistic research describing MOTS-c identity before mouse and human exercise experiments. A biological identity does not establish a health outcome from an external product. ↩ ↩²

12. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. Participants were randomized to endurance exercise, resistance exercise, or control, with blood and muscle sampling. A trend and a circulating measurement do not establish that MOTS-c caused a performance or longevity outcome. ↩ ↩² ↩³